Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...